Airspan Networks Expands 5G In-Motion Platform into Defense MANET, High-Altitude Platforms, and Drones February 25, 2026 Introducing a resilient advanced communications bridge between terrestrial and aerial networks
NYU Abu Dhabi and RTW Investments Announce Strategic Collaboration to Advance Healthcare and Life Sciences Innovation February 25, 2026 Partnership will deliver executive programs and convene global investors, policymakers, and experts to strengthen the region’s healthcare ecosystem
Aera Technology Named to The Hackett Group® 2025–2026 “50 to Watch” List for Procurement Innovation February 25, 2026 Recognized for Enabling Real-Time Procurement Decisions Across the Enterprise
Alkermes plc Announces CEO Succession Plan February 25, 2026 — Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair Jackson, Alkermes’ Current Executive Vice President, Chief Operating Officer, as CEO Effective as of August 1, 2026 — — Richard Pops to Continue to Serve as Chairman of the Alkermes Board of Directors —
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026 February 25, 2026 Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings press release and presentation please visit the company’s investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast [...]
Chemify and Sanacor Collaborate to Discover and Develop Small Molecule Therapies for Cardiometabolic Diseases February 25, 2026 Partnership to use Chemify’s programmable chemistry technology and Sanacor’s translational biology expertise to accelerate small-molecule discovery addressing mitochondrial dysfunction
IGI Declares Extraordinary Cash Dividend February 25, 2026 International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today announced that its Board of Directors has declared an extraordinary cash dividend of $1.15 per common share. The extraordinary dividend is payable on April 6, 2026 to shareholders of record at the close of business on March 18, 2026. About IGI: IGI is [...]
Ascensia Diabetes Care Appoints Peter Bodlund as President and Chief Executive Officer February 25, 2026 Ascensia Diabetes Care, a global diabetes care company and subsidiary of PHC Holdings Corporation (TSE: 6523), today announced the appointment of Peter Bodlund as President and Chief Executive Officer, effective April 1, 2026. He succeeds Koichiro Sato, who will continue in his roles as Chief Operating Officer of PHC Group and Head of PHC Group’s [...]
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 2025 February 25, 2026 Strong margin improvement to 16.3% in FY 2025 Positive growth outlook with continued margin expansion in 2026 New EUR 200 million share buyback
Luxfer Delivers Strong Full-Year 2025 Profitability and Cash Generation February 24, 2026 Portfolio focus and favorable mix drive sustained profitability, enhanced adjusted earnings growth and strong cash flow generation Fourth Quarter 2025 Highlights* Net Sales declined 12.3% to $90.7 million from $103.4 million, while Adjusted Net Sales1 declined 5.5% Net Income of $0.1 million, compared to $3.3 million, and $0.12 per diluted share, with Adjusted Diluted EPS1 of $0.28 down 3.4% from $0.29 Adjusted EBITDA1 of $13.0 million, declined 5.8% Continued execution of previously announced operational excellence initiatives, including the Riverside and Powders Saxonburg centers of excellence, expected to drive improved efficiency and generate approximately $6 million of long-term annual savings Full Year 2025 Highlights* Net Sales declined 1.9% to $384.6 million from $391.9 million, while Adjusted Net Sales1 increased 2.5% Net Income of $13.1 million, or $0.48 per diluted share, compared to $18.3 million and $0.68 per diluted share, with Adjusted Diluted EPS1 of $1.11, up 12.1% from $0.99 Adjusted EBITDA1 of $51.9 million, up 4.2% Delivered strong free cash flow of $26.2 million, reducing net debt to $31.1 million Enhanced portfolio quality and strategic focus following completion of the Graphic Arts sale * Comparative information is relative to prior-year fourth quarter and full year; results exclude discontinued operations 1 Note: Adjusted results exclude Graphic Arts and 2024 legal fee recoveries
